State biosimilar substitution laws could reduce consumer access and savings

State biosimilar substitution laws could reduce consumer access and savings

Collection:
Health Policy and Services Research
Series Title(s):
Fact sheet (AARP Public Policy Institute (Organization))
Author(s):
Purvis, Leigh, author
McSpadden, James, author
Contributor(s):
AARP (Organization), issuing body.
Public Policy Institute (AARP (Organization)), issuing body.
Publication:
Washington, DC : AARP Public Policy Institute, October 2022
Language(s):
English
Format:
Text
Subject(s):
Biosimilar Pharmaceuticals
Cost Savings
Health Services Accessibility
Legislation, Drug
Drug Costs
State Government
United States
Genre(s):
Technical Report
Abstract:
Biosimilar drugs are less expensive but equally safe and effective substitutes for expensive biologic drugs. Yet biosimilars that qualify for automatic substitution often have to meet more stringent state substitution requirements than traditional generic drugs. This differential treatment in state laws could contribute to lingering concerns about biosimilars and unnecessarily reduce consumer access to and savings from these increasingly important products.
Copyright:
Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY-NC-ND license. (More information)
Extent:
1 online resource (1 PDF file (8 pages)).
NLM Unique ID:
9918557282006676 (See catalog record)
Permanent Link:
http://resource.nlm.nih.gov/9918557282006676